Neocarzinostatin (NCS) is an antitumor polypeptide isolated from the culture beer of Streptomyces carcinostaticus var. F-41.1 Its chemical characterization4,5. 8-10 and mode of action6 ,11,12 have been reported previously by our group. NCS was subjected to extensive preclinical investigation and was shown to have a marked effect on a number of transplantable rodent tumors.1 2 7 13 The present report describes the results of preliminary clinical trials in 17 patients with malig nant neoplasms METHODS Neocarzinostatin (NCS) was supplied in ampoule containing 2 mg of dry substance prepared at the Kayaku Antibiotic Research Laboratory (Tokyo). The drug was kept in dry-ice-box for storage and transportation. It was readily soluble in isotonic saline or 20% glucose solution. The dose of NCS given to most patients was 2 mg per day per person by intravenous injection for 10 to 17 days, and this treatment was repeated at appropriate intervals for one or two weeks.
The present report is concerned with the results obtained from 17 adult patients with malignant tumors hospitalized in the Yonezawa City Hospital and treated with NCS. Case 3. Carcinoma o f the rectun. The patient was a 74-year-old woman. The diagnosis of adenocarcinoma of the rectum was made by romanoscopy and exfoliative cytology in February, 1968. The patient had mucinous diarrhea with blood, marked pain of the lower abdomen, and a severe loss of body weight. A total amount of 20 mg of NCS was administered. The details are given in Table 2 . Progressive improvement in the clinical symptoms occurred, and within 2 weeks her complaint disappeared.
Half a month after the termination of treatment, a romanoscopic examination revealed marked reduction of the tumor in the rectum. Now, eight months after the beginning of therapy, she has no clinical symptoms and leads healthy life, although she has still a large tumor of the rectum with scattered foci of cicatrization.
Case 4. Carcinoma of the stop ach. A 57-year-old man, first examined at the Hospital in December 1967, complained of chronic anorexia, chest pain like inter costal neuralgia and loss of body weight. Roentgenogram of the stomach and gastroscope-camera examination revealed a round-shape tumor of about 7 cm in diameter with necrotic surface at the angle of the stomach. Cytological examina tion of gastric washings showed malignant cells. The chest roentgenogram revealed a lesion in the field of middle thoracic vertobrae indicative of a metastasis. He was initially treated with niitomycin C (MM) for 6 days in January 1968. At the sixth administration of the drug (MM), he complained of severe hematemesis without any improvement of the disease, so that the treatment was discontinued. Two months after the termination of the MM therapy (March, 1968), the patient received NCS injection. Within a few days, the chest pain completely disappeared, and 2 weeks later he was relieved from anorexia, nausea, vomiting or signs of gastric bleeding. Roentogenogram and gastrocamera examinations in May 1968 proved that gastric tumor masses had markedly decreased in size, although they had Case 13. Carcinoma of the tongue. The patient was a 7l-year-old man who had received a radical operation of carcinoma of the tongue in November 1967 at the Hospital. He again visited the Hospital in May 1968. Then lie complained of difficulty in swallowing, pharyngeal pain and marked swelling of submaxillar lymph nodes. His clinical. history and biopsy of the submaxillar nodes proved metastatic carcinoma. NCS was administered, as shown in detail in Table 2 . There was a, gradual decrease of the tumor masses of the lymph nodes and i m provement of swallowing, but definite evidence of regrowth of the neck tumors was observed one month after the initial therapy. The patient failed to respond to the second course of NCS administration. Death was due to progressive cancer.
Case 15. Carcinama in the pelvic bone. The patient was a 68-year-old man, and the diagnosis of metastatic _ carcinoma was made by biopsy of the tumor in the pelvic bone in December 1967, although a primary focus was not ascertained. In January 1968, he complained of difficulties in his gait which caused severe ischias-like pain. He was initially treated with localized radiotherapy and endoxan without any improvement. The patient received the first course of NCS therapy in March 1968. A marked decrease in the size of nodular lesions in the pelvis was observed by roentogenogram after the course. There was gradual relief of pelvic pain and improvement in the gait. The patient received a second course of therapy with two weeks' interval after the first course of NCS treatment. One month after the termination of the second course of NCS therapy, he did not complain of any pain and he was able to walk. However, recurrence of the lesion in the pelvis occurred and the patient failed to respond to the third course of NCS therapy.
Case 16. Cancer of the liver and colon. A 38-year-old woman first visited the Hospital in January 1968. She complained of raucous bloody stool, meteorism and enlargement of the liver to 6 finger width. Because of anorexia and severe loss of body weight she could not walk unsupported. The patient received two courses of NCS treatment (Table 2) . After the first course, enlargement of the liver decreased from 6 to 3 finger width. Pains in the abdomen and bloody stool ceased to occur and her appetite surprisingly improved, resulting in a marked increase of body weight. Two weeks after termination of the first course of treat ment, regrowth of liver tumor and development of jaundice were noticed and the second course of therapy was started. Jaundice completely disappeared and improvement in physical activity was observed in two days after the termination of the second course, but other objective signs did not regress so far. The patient died three months after the therapy.
Therapeutic results of the other two cases are as follows: Case No. 6, under the diagnosis of esophagocardial carcinoma, received three courses of NCS treatment in total and the patient was alive 6 months after beginning of the NCS-therapy. In this case, the disappearance of difficulties in swallowing, vomiting and epigastral pain were seen, whenever the NCS-treatment was started and the tumor growth in the stomach was inhibited during the observation period, although the decrease of the tumor size was not observed by means of either roentgenography or gastrocamera.
In. Case 17 of acute myeloid leukemia, the patient received NCS in combination with 6-mercaptopurine (6MP). After the administration of 45 mg NCS and 4,000 mg of 6MP, splenomegaly and pathologic white cells in the peripheral blood completely disappeared. However, the effect of NCS therapy could not be evaluated, on account of the combination therapy. Besides the 7 cases described above, subjective improvement of general condi tions was noted in the rest and some physical examinations indicated transient improvement in Cases I and 12 (Table 5) , whereas no objective improvement was observed. The observation that NCS was effective to tumors resistant to other chemo therapeutics or radiation suggests the absence of cross resistance at least to some other drugs and x-ray. This assumption is in agreement with the observation by Bradner2 that no cross resistance to NCS was seen in sublines of L121.0 resistant to one or more well-known antitumor antimetabolites.
Although Case 17 was excluded from the clinical evaluation of NCS-therapy owing to simultaneous administration of other drugs (Table 2) , the marked improvement in this case suggests the combination effect with 6MP and NCS in human leukemia. Such an effect is also expected from the existence of collateral sensitivity to NCS in sublines of L1210 resistant to 6MP and the combination effect of the two drugs in L1210 in mice. ' At present, limited experience with NCS does not permit an evaluation of the effect of NCS against hepatoma. A phase III study for hepatomas or metastatic tumors of the liver is now scheduled in Japan. 
